tiprankstipranks
Trending News
More News >

Fusion Pharmaceuticals downgraded to Neutral from Buy at B. Riley

B. Riley analyst Yuan Zhi downgraded Fusion Pharmaceuticals (FUSN) to Neutral from Buy with a price target of $23, up from $13. Based on existing collaboration on Ac225-labelled bispecifics, B. Riley believes Fusion’s FPI-2265 fits nicely in AstraZeneca’s (AZN) prostate cancer franchise, the analyst tells investors in a research note, adding that Fusion shares are being acquired in a fair value range.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1